Celgene Corporation (CELG) Shares Sold by Bp Plc
Bp Plc reduced its stake in Celgene Corporation (NASDAQ:CELG) by 5.9% in the 2nd quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 112,000 shares of the biopharmaceutical company’s stock after selling 7,000 shares during the quarter. Bp Plc’s holdings in Celgene Corporation were worth $14,544,000 as of its most recent SEC filing.
Other institutional investors also recently made changes to their positions in the company. Harel Insurance Investments & Financial Services Ltd. acquired a new position in Celgene Corporation in the 1st quarter worth approximately $118,000. Acropolis Investment Management LLC acquired a new position in Celgene Corporation in the 2nd quarter worth approximately $144,000. Mitsubishi UFJ Securities Holdings Co. Ltd. increased its holdings in Celgene Corporation by 47.5% in the 1st quarter. Mitsubishi UFJ Securities Holdings Co. Ltd. now owns 1,180 shares of the biopharmaceutical company’s stock worth $147,000 after buying an additional 380 shares during the period. Oakworth Capital Inc. increased its holdings in Celgene Corporation by 11.7% in the 2nd quarter. Oakworth Capital Inc. now owns 1,216 shares of the biopharmaceutical company’s stock worth $158,000 after buying an additional 127 shares during the period. Finally, Smithfield Trust Co. increased its holdings in Celgene Corporation by 35.7% in the 2nd quarter. Smithfield Trust Co. now owns 1,229 shares of the biopharmaceutical company’s stock worth $160,000 after buying an additional 323 shares during the period. 79.36% of the stock is owned by hedge funds and other institutional investors.
In related news, Director Ernest Mario sold 18,506 shares of the company’s stock in a transaction on Thursday, August 10th. The stock was sold at an average price of $130.52, for a total transaction of $2,415,403.12. Following the transaction, the director now owns 69,424 shares of the company’s stock, valued at $9,061,220.48. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, insider Terrie Curran sold 1,727 shares of the company’s stock in a transaction on Monday, September 25th. The stock was sold at an average price of $143.89, for a total value of $248,498.03. Following the transaction, the insider now directly owns 3,925 shares in the company, valued at approximately $564,768.25. The disclosure for this sale can be found here. Insiders have sold 46,233 shares of company stock worth $6,268,259 in the last ninety days. 0.95% of the stock is currently owned by corporate insiders.
COPYRIGHT VIOLATION NOTICE: “Celgene Corporation (CELG) Shares Sold by Bp Plc” was posted by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are accessing this story on another publication, it was illegally copied and reposted in violation of U.S. and international copyright and trademark legislation. The legal version of this story can be read at https://www.thecerbatgem.com/2017/10/08/celgene-corporation-celg-shares-sold-by-bp-plc.html.
CELG has been the topic of several research reports. BTIG Research downgraded shares of Celgene Corporation from a “buy” rating to a “neutral” rating and increased their price target for the stock from $96.93 to $131.70 in a report on Friday, June 30th. Leerink Swann reiterated an “outperform” rating and issued a $160.00 price target (up previously from $150.00) on shares of Celgene Corporation in a report on Friday, July 28th. Argus upgraded shares of Celgene Corporation from a “hold” rating to a “buy” rating and increased their price target for the stock from $96.93 to $160.00 in a report on Monday, July 31st. Credit Suisse Group set a $148.00 price target on shares of Celgene Corporation and gave the stock a “buy” rating in a report on Thursday, July 6th. Finally, Stifel Nicolaus initiated coverage on shares of Celgene Corporation in a report on Friday, July 28th. They issued a “buy” rating and a $155.00 price target on the stock. Two research analysts have rated the stock with a sell rating, five have issued a hold rating and twenty-two have issued a buy rating to the company. Celgene Corporation currently has a consensus rating of “Buy” and an average target price of $150.60.
Shares of Celgene Corporation (NASDAQ:CELG) opened at 139.21 on Friday. The company has a 50-day moving average of $139.31 and a 200-day moving average of $129.53. Celgene Corporation has a 1-year low of $96.93 and a 1-year high of $147.17. The firm has a market cap of $108.91 billion, a PE ratio of 43.11 and a beta of 1.88. Celgene Corporation also was the recipient of unusually large options trading on Thursday. Investors acquired 12,607 put options on the company. This is an increase of approximately 260% compared to the average volume of 3,499 put options.
Celgene Corporation (NASDAQ:CELG) last announced its quarterly earnings data on Thursday, July 27th. The biopharmaceutical company reported $1.82 earnings per share for the quarter, topping the Zacks’ consensus estimate of $1.61 by $0.21. Celgene Corporation had a return on equity of 68.51% and a net margin of 21.35%. The firm had revenue of $3.27 billion for the quarter, compared to analyst estimates of $3.23 billion. During the same quarter in the prior year, the company posted $1.44 earnings per share. Celgene Corporation’s quarterly revenue was up 18.7% on a year-over-year basis. Analysts predict that Celgene Corporation will post $7.32 earnings per share for the current fiscal year.
Celgene Corporation Profile
Celgene Corporation is an integrated global biopharmaceutical company. The Company, together with its subsidiaries, is engaged in the discovery, development and commercialization of therapies for the treatment of cancer and inflammatory diseases through solutions in protein homeostasis, immuno-oncology, epigenetics, immunology and neuro-inflammation.
Want to see what other hedge funds are holding CELG? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Celgene Corporation (NASDAQ:CELG).
Receive News & Stock Ratings for Celgene Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celgene Corporation and related stocks with our FREE daily email newsletter.